Common insecticides have been linked in studies to neurodevelopmental disorders.

Published Date: 26 Apr 2023

According to a recent study from The University of Toledo, even at levels that are currently recognized, early exposure to the common class of insecticides known as pyrethroids may increase the risk of autism and other developmental disorders.

Read Full News

Latest News

NeurologyLive® Year in Review 2025: Spotlighting SAP Collaborations Isabella Ciccone, MPH

As part of NeurologyLive®'s Year in Review, take a look at our top collaborative interviews with the Strategic Alliance Partnership program in 2025.

NeurologyLive® Year in Review 2025: Most Impactful FDA Decisions Isabella Ciccone, MPH

These were the most impactful FDA approval stories that were part of our coverage in 2025, brought to you as part of NeurologyLive's Year in Review.

Phase 3 REVITALYZ Trial of Once-Nightly Sodium Oxybate in Idiopathic Hypersomnia Finishes Enrollment Marco Meglio

Avadel's REVITALYZ trial for Lumryz in idiopathic hypersomnia shows promise, potentially offering a new treatment option for this underserved condition.

NeurologyLive® Year in Review 2025: Conference Coverage Recap NeurologyLive® Staff

NeurologyLive® provided in-depth coverage of conferences in 2025, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

NeurologyLive® Brain Games: December 28, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on RBD as a prodromal marker for synucleinopathies!

Wnt/β-catenin in Multiple Sclerosis: A Nuanced Approach to Remyelination Kevin Chang, PharmD

In this Neuropathways piece, Kevin Chang, PharmD, explores the complexities of remyelination in multiple sclerosis and the potential of Wnt/β-catenin signaling as a therapeutic target.

Todays Updates

NeurologyLive® Year in Review 2025: Top trending Migraine Trials NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review 2025, we've compiled some of the top trending migraine trials.

NeuroVoices: David A. Hafler, MD, FANA, on Understanding MS as an Autoimmune and Neurodegenerative Disease Isabella Ciccone, MPH, David A. Hafler, MD, FANA

At ECTRIMS 2025, the William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine discussed evolving insights into the disease pathogenesis of multiple sclerosis.

NeurologyLive® Year in Review 2025: Top Interviews on the AI Takeover Isabella Ciccone, MPH

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews on the latest advances and use of artificial intelligence in neurology care.

Fibromyalgia in 2025: Year in Review

Fibromyalgia in 2025: Year in Review

Rheumatoid Arthritis in 2025: Year in Review

Rheumatoid Arthritis in 2025: Year in Review

Asthma in 2025: Year in Review

Asthma in 2025: Year in Review

C3 Glomerulopathy in 2025: Year in Review

C3 Glomerulopathy in 2025: Year in Review

Todays Updates

NeurologyLive® Year in Review 2025: Top trending Migraine Trials NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review 2025, we've compiled some of the top trending migraine trials.

NeuroVoices: David A. Hafler, MD, FANA, on Understanding MS as an Autoimmune and Neurodegenerative Disease Isabella Ciccone, MPH, David A. Hafler, MD, FANA

At ECTRIMS 2025, the William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine discussed evolving insights into the disease pathogenesis of multiple sclerosis.

NeurologyLive® Year in Review 2025: Top Interviews on the AI Takeover Isabella Ciccone, MPH

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews on the latest advances and use of artificial intelligence in neurology care.

Fibromyalgia in 2025: Year in Review

Fibromyalgia in 2025: Year in Review

Rheumatoid Arthritis in 2025: Year in Review

Rheumatoid Arthritis in 2025: Year in Review

Asthma in 2025: Year in Review

Asthma in 2025: Year in Review

C3 Glomerulopathy in 2025: Year in Review

C3 Glomerulopathy in 2025: Year in Review

Latest News

As part of NeurologyLive®'s Year in Review, take a look at our top collaborative interviews with the Strategic Alliance Partnership program in 2025.

These were the most impactful FDA approval stories that were part of our coverage in 2025, brought to you as part of NeurologyLive's Year in Review.

Avadel's REVITALYZ trial for Lumryz in idiopathic hypersomnia shows promise, potentially offering a new treatment option for this underserved condition.

NeurologyLive® provided in-depth coverage of conferences in 2025, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on RBD as a prodromal marker for synucleinopathies!

In this Neuropathways piece, Kevin Chang, PharmD, explores the complexities of remyelination in multiple sclerosis and the potential of Wnt/β-catenin signaling as a therapeutic target.

News All Time

What’s All the Buzz? Trending Topics and Phrases of Neurology in 2025 Marco Meglio

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.

Adults with Developmental and Epileptic Encephalopathies in the Precision Treatment Era Danielle Andrade, MD, MSc

Explore the evolving landscape of developmental and epileptic encephalopathies in adults, highlighting precision therapies and the need for accurate diagnoses.

Brain-Penetrant Molecule GT-02287 Demonstrates Reversal of Glucosylsphinogosine in Parkinson Disease Marco Meglio

Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.

Remyelinating Agent PIPE-307 Falls Short in Phase 2 Trial of Relapsing Multiple Sclerosis Marco Meglio

Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.

This Week on NeurologyLive® — December 22, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

CAPN2-Targeting Agent AMX0114 Shows Safe Profile in Phase 1 LUMINA Trial of ALS Marco Meglio

New findings from the LUMINA trial reveal AMX0114's safety in ALS patients, paving the way for further research and potential treatment advancements.

NeurologyLive® Brain Games: December 21, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neuromodulation for Parkinson disease!

Frontlines with Frontera: Using Artificial Intelligence to Rethink Seizure Management in the Neuro ICU Jennifer Frontera, MD, Sahar Zafar, MD, MBBS

Frontlines with Frontera, a podcast hosted by neurointensivist Jennifer Frontera, MD, brings you an exclusive interview with Sahar Zafar, MD, MBBS. [LISTEN TIME: 30 minutes]

NeurologyLive® Friday 5 — December 19, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 19, 2025.

Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook Marco Meglio

GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.

FDA Expands Indication for n‐Butyl Cyanoacrylate in Chronic Subdural Hematoma Isabella Ciccone, MPH

The expanded indication brings n-butyl cyanoacrylate’s established performance into the treatment of chronic subdural hematoma, a condition for which traditional surgical interventions may not always be suitable or effective.

Phase 3b STRENGTH Trial Provides Greater Support for Intrathecal SMA Gene Therapy Marco Meglio

Phase 3b study revealed Itvisma's safety and efficacy in treating spinal muscular atrophy, showing modest motor function improvements in patients previously on other therapies.

NeuroVoices: Alireza Atri, MD, PhD, on Notable CTAD Trial Presentations, EVOKE Data Alireza Atri, MD, PhD, Isabella Ciccone, MPH

The director of the Banner Sun Health Research Institute discussed a variety of meaningful Alzheimer disease research presented at the 2024 Clinical Trials on Alzheimer's Disease Conference (CTAD).

What the First Intrathecal Gene Therapy Means for SMA Clinicians and Researchers Marco Meglio

Angela Lek, PhD, chief research officer of the Muscular Dystrophy Association, discusses the FDA approval of intrathecal onasemnogene abeparvovec (Itvisma; Novartis) and what it means for SMA treatment across older pediatric and adult populations.

Genetic Testing in Adult Epilepsy: GEAN’s Plan to Standardize Practice and Study Adult Outcomes Marco Meglio

Elizabeth Gerard, MD, an epileptologist at Northwestern Medicine, provided clinical insights on a new consortium, GEAN, which aims to expand genetic testing and define adult phenotypes for rare genetic epilepsies across North America.

A Clinical Review of the 2025 Restless Leg Syndrome Guidelines Louie Pasculli, Andy Berkowski, MD, PhD

Andy Berkowski, MD, PhD, certified sleep neurologist and author of the RLS guidelines, spoke about the clinical impact of the recently published restless syndrome guidelines.

Recommended News For You

A new way to measure suicide risk?

Atezolizumab + Cabozantinib Postpones mCRPC Progression.

What Dolph Lundgren's journey from terminal diagnosis to 'cancer free' can tell us about cancer care

Additional imaging techniques can detect early stage cancers missed by mammograms in women with dense breasts

EU Adds CAR-T Warning; New Blincyto Indication; Good News in Pancreatic Cancer

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests.

According to JAMA, women who have false-positive mammogram results are at a higher risk of developing breast cancer over time.

Recommended Articles For You

The Benefits of Understanding Haptoglobin High: What You Need to Know 

The Unfolding Revolution of Precision Medicine, Immunotherapy, and Digital Transformation in Medical Oncology 2025 

Emerging Therapies and Technologies Reshaping Oncology: Innovations and Impact in 2025 

Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A better option for mild to moderate depression?

2.

Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat

3.

Stevia leaf extract has potential as anticancer treatment, researchers find

4.

A US health panel advises starting mammograms at age 40 rather than 50.

5.

Some triple negative breast cancers might be avoided by longer breastfeeding

1.

Diagnosis and Treatment of Follicular Thyroid Cancer: A Comprehensive Guide

2.

Exploring the Normal Range of Monocytes: A Comprehensive Guide

3.

Unraveling the Mysteries of Metastasis: Exploring the Latest Advances in Cancer Research

4.

Hemoglobin C: Understanding its Role in Sickle Cell Disease

5.

Neutrophil Profiling and AI Rewrites Cancer Diagnosis

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

First Line Combination Therapy- The Overall Survival Data in NSCLC Patients

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

3.

Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations

4.

A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

5.

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot